CMDBioscience is a computational biotechnology company that specializes in the development and application of proprietary computational methods to analyze, model and design protein-peptide interactions of interest to the pharmaceutical, biotechnology and life science industries.  Using our proprietary computational peptide discovery platform CMDInventusSM, CMD scientists can help partner organizations efficiently identify novel peptide hits, understand the structural basis of protein-peptide interactions, and rationally optimize peptide hits into viable lead compounds.

LaunchCapital Connection: Konstantine Drakonakis

visit website